Nicola Curry

Jul 30, 2024 | digitalcommons.library.tmc.edu | Ross Davenport |Nicola Curry |Erin Fox |Helen Thomas

IMPORTANCE: Critical bleeding is associated with a high mortality rate in patients with trauma. Hemorrhage is exacerbated by a complex derangement of coagulation, including an acute fibrinogen deficiency. Management is fibrinogen replacement with cryoprecipitate transfusions or fibrinogen concentrate, usually administered relatively late during hemorrhage.

Jun 20, 2024 | emj.bmj.com | Ross Davenport |Nicola Curry |Oxford Haemophilia

Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

May 23, 2024 | emj.bmj.com | Ross Davenport |Nicola Curry |Oxford Haemophilia

Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Mar 26, 2024 | onlinelibrary.wiley.com | Cedric Hermans |Jill M. Johnsen |Nicola Curry

DISCLOSURES Cedric Hermans: research funding: Bayer, BioMarin, CSL Behring, Novo Nordisk, Pfizer, Shire/Takeda, and Sobi; honoraria and speaker's bureau: Bayer, CAF-DCF, CSL Behring, Hoffmann-La Roche, LFB, Novo Nordisk, Octapharma, Pfizer, Shire/Takeda, Sobi, and UniQure. Jill Johnsen: research funding: Octapharma and consultancy: Octapharma, Takeda, CSL Behring, Biomarin.

Oct 12, 2023 | jamanetwork.com | Ross Davenport |Nicola Curry |Erin Fox |Helen Thomas

Key PointsQuestion  Does transfusion of early and empirical high-dose cryoprecipitate in addition to standard care improve survival in bleeding patients with trauma who require activation of a major hemorrhage protocol? Findings  In this multicenter, international, randomized clinical trial of 1604 patients with trauma comparing standard care vs usual care plus 3 early pools of cryoprecipitate, there was no difference in all-cause 28-day mortality (26.1% vs 25.3%).